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 ABSTRACT  
 Objectives  Interleukin-1 receptor-associated kinase 
(IRAK)-M suppresses Toll-like receptor (TLR)-mediated 
activation of innate immunity during infection. A similar 
role was hypothesised for IRAK-M in autoimmunity. 
 Methods  Irak-m-defi cient mice were crossed with 
autoimmune C57BL/6-lpr/lpr mice and detailed phenotype 
analysis was performed. 
 Results  Irak-m defi ciency converted the mild 
autoimmune phenotype of C57BL/6-lpr/lpr mice into 
a massive lymphoproliferative syndrome with lethal 
autoimmune lung disease and lupus nephritis. Irak-m 
defi ciency induced a number of interferon-related genes, 
cytokines and plasma cell survival factors in spleen cells 
of these mice. Irak-m-defi cient C57BL/6-lpr/lpr mice 
showed expansion of autoreactive T cells, dysfunctional 
regulatory T cells and plasma cells which was associated 
with increased lupus autoantibody production. TLR7 
antagonism almost completely abrogated this phenotype 
consistent with IRAK-M-mediated suppression of TLR7 
signalling in vitro. 
 Conclusions  These data identify a previously unknown 
function of IRAK-M—namely, suppression of TLR7-
mediated autoimmunity—and mutant IRAK-M as a 
previously unknown genetic risk for murine SLE. 
 INTRODUCTION 
 Autoimmunity means loss of tolerance against self-
antigens by, for example, the presence of autoan-
tibodies. Transient autoimmunity is common, but 
whether or not it manifests as autoimmune tissue 
injury depends on the signals and genetic factors 
that regulate the expansion of autoreactive lym-
phocytes. 1  2 For example, in systemic lupus erythe-
matosus (SLE), loss of tolerance affects ubiqitous 
nuclear autoantigens and can result in a spectrum 
of clinical manifestations ranging from mild skin 
rashes and arthralgia to severe infl ammation of the 
kidney, lungs or brain. 3 SLE develops when gene 
variants promote the exposure of nuclear particles 
to the immune system—for example, defects in 
apoptosis, in opsonisation of dying cells, in phago-
cytosis or in extracellular nuclease activity. 4 Other 
genetic risk factors affect immune recognition of 
self-nucleic acids by Toll-like receptors (TLR), sub-
sequent danger signalling and the production of 
type I interferons, 5 a process that also enhances the 
presentation of nuclear autoantigens and the sub-
sequent expansion of autoreactive lymphocytes. 6 A 
third class of genetic factors promote tissue infl am-
mation and damage. 4 Combinations of genetic 
polymorphisms in either weak or potent suscepti-
bility genes account for the variable disease onset 
and clinical manifestation patterns in human SLE. 
For example, a genome-wide association study in 
1311 patients with SLE and 3340 control subjects 
identifi ed HLA, STAT4, IRF5, BLK and ITGAM-
ITGAX as variant genes with a particularly strong 
association with SLE. 7 
 Murine studies have been used to identify the 
relative importance of single genes for SLE. For 
example, potent susceptibility genes such as trans-
forming growth factor β 1 (TGF-β 1 ), DNase1, Lyn, Fas 
or C1q were identifi ed because they were suffi cient 
to cause lupus-like autoimmunity in the absence 
of additional predisposing factors. 8 – 13 Lupus risk 
genes are less potent when they require a second 
genetic factor to trigger SLE—that is, genes such as 
SLE1, TLR7, TLR9 or SIGIRR. 14 – 17 Weaker disease 
modifi er genes such as interleukin (IL)-10 or IL-27R 
enhance SLE only together with other susceptibility 
genes, for example, being provided by the specifi c 
autoimmune genetic background of MRL mice. 18  19 
 The interleukin-1 receptor-associated kinases 
(IRAK) have important roles in innate immunity 
because they regulate signal transduction of the 
IL-1R and the TLRs. For example, the MyD88 sig-
nalling pathway requires IRAK-4 to phosphorylate 
TRAF6, 20 which is inhibited by another member 
of the IRAK family, IRAK-M, in cells of the mono-
cyte/macrophage lineage. 21  22 IRAK-M induction 
contributes to endotoxin tolerance 21  22 and sepsis-
induced 23 or tumour-associated immunosuppres-
sion. 24 IRAK-M also limits infection-associated 
immunopathology 25 and prevents osteoporosis by 
suppressing osteoclast differentiation. 26 Consistent 
with these immunosuppressive effects, loss of 
function mutations in the human IRAK-M gene are 
associated with inappropriate immunopathology 
such as in asthma. 27 Interestingly, genome-wide 
association studies located as yet unknown lupus 
risk factors to the IRAK-M gene locus at chromo-
some 12p14. 7 We therefore hypothesised a role for 
IRAK-M beyond the control of microbial defence 
in the suppression of inadequate TLR signalling 
in antigen-presenting cells (APCs), a recently dis-
covered pathomechanism of autoimmunity. 6 We 
approached this hypothesis by characterising the 
phenotype of  Irak-m -defi cient C57BL/6  lpr/lpr  (B6  lpr  ) 
mice in which the  lpr mutation fosters autoantibody 
production and mild autoimmune tissue injury. 8 
 METHODS 
 Animal studies 
 Irak-m -defi cient mice were generated as previously 
described 21 and back-crossed to the C57BL/6 strain 
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(B6; Charles River Laboratories, Sulzbach Germany) to the F10 
generation. B6  lpr/Irak-m-/-  and B6  lpr  mice (Charles River) were 
mated to generate B6  lpr/Irak-m-/+  mice which were then mated 
among each other to generate B6  lpr/Irak-m+/+  and B6  lpr/Irak-m-/-  mice. 
Littermates were used for all experimental procedures. In each 
individual mouse the genotype was assured by PCR. Mice were 
housed in groups of fi ve in sterile fi lter top cages with a 12 h 
dark/light cycle and unlimited access to autoclaved food and 
water. Power calculations performed on the primary endpoint 
(the ‘lupus nephritis activity index’) determined a group size of 
17. One cohort of mice was killed by cervical dislocation at 24 
weeks of age and one cohort was followed until 52 weeks of 
age. Other groups of B6  lpr  and B6  lpr/Irak-m-/-  mice were treated 
by intraperitoneal injection either with saline or with the TLR7 
blocking phosphothioate oligodeoxyribonucleotide IRS 661 
(5′-TGCTTGCAAGC TTGCAA-GCA-3′; TIB Molbiol, Berlin, 
Germany) at a dose of 40 μg on alternate days from weeks 13–24 
of age as described elsewhere. 28 IRS 661 prevents the activation 
of dendritic cells and B cells of lpr mice upon exposure to TLR7 
agonists, 28  29 and the dose selected was previously shown to be 
effective in vivo. 28 All experimental procedures were performed 
according to the German animal care and ethics legislation and 
had been approved by the local government authorities. 
 In vitro experiments 
 Spleen monocytes from wild-type and  Irak-m -defi cient mice 
were kept in RPMI medium with 10% fetal calf serum and 1% 
penicillin/streptomycin. 5×10 6 cells in 12-well plates were stimu-
lated for 24 h with the TLR4 agonist ultrapure lipopolysaccharide 
(LPS, 1 μg/ml; Invitrogen, Karlsruhe, Germany), the TLR7 agonist 
imiquimod (1 μg/ml; Sequoia Research Products Ltd, Oxford, UK) 
or the TLR9 agonist CpG-DNA (1 μg/ml; Invitrogen). Y12 and 
snRNP (Arotec, Wellington, New Zealand) were used in concen-
trations of 5 μg/ml and 10 μg/ml, respectively. IL-6 and tumour 
necrosis factor α (TNFα) concentrations were determined in cell 
supernatants by ELISA following the manufacturer’s protocols 
(OptEiA; BD Biosciences, Heidelberg, Germany). 
 Flow cytometry 
 Anti-mouse CD3, CD4, CD8 and CD25 (BD Pharmingen, 
Heidelberg, Germany) antibodies were used to detect 
CD3+CD4−CD8– double negative T cells and CD4+CD25+/
Foxp3 regulatory T cell (Treg) populations in the spleen. CD11c 
was stained to identify plasmacytoid and myeloid dendritic cells 
and their activation was assessed by co-staining for CD40 and 
MHC II (BD Pharmingen). Dendritic cell subtypes were identi-
fi ed using CD4 and CD8a co-stained with CD11c. Anti-mouse 
B220, CD21, CD23, IgD and IgM antibodies (BD Pharmingen) 
were used to identify B cell subsets from a spleen single cell sus-
pension. Anti-mouse κ light chain and CD138 (BD Pharmingen) 
were used to identify plasma cells. F4/80, CD11b and MHC II 
(BD Pharmingen) were used to identify macrophage activation. 
Activated B cells were identifi ed with co-staining of B220, CD19 
and CD69 (BD Pharmingen) and T cell activation was identifi ed 
with CD69 co-stained with T cell markers shown above. An 
Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen) was 
used to identify apoptotic cells. Respective isotype antibodies 
were used to demonstrate specifi c staining of cell subpopula-
tions. Cell counting beads (Invitrogen) were used for cell count-
ing by fl uorescence-activated cell sorting (FACS). 
 T cell proliferation assays 
 CD4+CD25+ Treg cells and CD4+CD25 neg T effector (Teff) cells 
from the spleen were purifi ed by two-step magnetic cell sorting 
(Miltenyi Biotec, Bergisch Gladbach, Germany). The remain-
ing cells were used as APCs. CD4+CD25 neg Teff cells (7.5×10 4 
cells) were activated with anti-CD3 antibody (0.1 μg/ml, clone 
500A2, BD Biosciences) in the presence of APCs (2×10 4 cells) 
and increasing numbers of CD4+CD25+ Tregs (5–40 × 10 3 cells) 
as described previously. 30 The cells were then co-cultured for 60 
h in the presence of BrdU (Sigma-Aldrich, Steinheim, Germany). 
BrdU incorporation into CD4+FoxP3 neg Teff cells was detected 
by fl ow cytometry using a Regulatory T Cell Staining Kit (eBio-
science, San Diego, California, USA). After incubation with 
Pacifi c Blue-labelled FoxP3 antibody, the cells were fi xed with 
1% paraformaldehyde (PFA) in phosphate-buffered saline (PBS), 
incubated with DNase I (Sigma-Aldrich) and stained with anti-
BrdU-FITC antibody (Invitrogen). Analysis was performed using 
a FACSCanto II fl ow cytometer (BD Biosciences) and FlowJo 
software (TreeStar, Ashland, Oregon, USA). 
 Evaluation of autoimmune tissue injury 
 Spleens were frozen in liquid nitrogen and cut in 7 μm sections. 
Slides were fi xed in acetone at 4°C for 10 min at room tempera-
ture, placed in PBS for 5 min and blocked with 5% goat serum 
in PBS for 20 min. The following primary antibodies were used 
for staining (all from BD): anti-mCD11c (clone HL3, 1:50), anti-
mCD3e (clone 500A2, 1:50) and anti-mCD19 (clone1D3, 1:50). 
Secondary antibodies used for staining were (all from Invitrogen): 
Alexa Fluor 647 goat anti-rat IgG (1:200), Alexa Fluor 488 goat 
anti-hamster IgG (1:200) and streptavidin Alexa Fluor 555 con-
jugate (1:200). Sections were mounted with Vectashield con-
taining 4′,6-diamidino-2-phenylindole (DAPI). The slides were 
scanned using an Olympus BX 61 microscope and recorded via 
CellP software; the scans underwent digital morphometry using 
Adobe Photoshop. Lungs and kidneys from all mice were fi xed 
in 10% buffered formalin, processed and embedded in paraf-
fi n. Two μm sections for periodic acid-Schiff (PAS) staining were 
prepared following routine protocols. The severity of the renal 
lesions was graded using the activity and chronicity indices for 
human lupus nephritis as described previously. 31 Serum IL-12 
levels were determined by ELISA following the manufacturer’s 
protocol (OptEiA; BD Biosciences). 
 Autoantibody analysis 
 Serum antibody levels were determined by ELISA as described 
elsewhere. 17 
 Anti-dsDNA antibodies: NUNC maxisorp ELISA plates were 
coated with poly-L-lysine (Trevigen, Gaithersburg, Maryland, 
USA) and mouse embryonic stem cell dsDNA. After incubation 
with mouse serum, dsDNA-specifi c IgG, IgG 1 , IgG 2a/c , IgG 2b , 
IgG 3 and serum IgG levels were detected by ELISA (Bethyl Labs, 
Montgomery, Texas, USA). 
 Critidiae luciliae assay: 1:50 diluted serum was applied to fi xed 
 C luciliae slides (BioRad Laboratories, Redmond, Washington, 
USA). Binding to  C luciliae kinetoplast was detected with 
FITC-conjugated goat anti-mIgG (1:1000, Invitrogen, Eugene, 
Oregon USA). DAPI staining (Vector Laboratories, Burlingame, 
California, USA) allowed co-localisation with kinetoplast 
dsDNA. For quantitation of kinetoplast staining intensity a 
semiquantitative score from 0 to 3 was used. 
 Anti-Sm: NUNC maxisorp ELISA plates were coated with 
Smith (Sm) antigen (Immunovision, Springdale, Arkansas, 
USA). The Sm IgG (Y12) antibody (GeneTex, San Antonio, 
Texas, USA) was used for standard. A horseradish peroxidase-
conjugated goat anti-mouse IgG (Rockland, Gilbertsville, 
Pennsylvania, USA) was used for detection. The same 
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procedure was followed for anti-SmRNP, anti-nucleosome 
and anti-Sm but ELISA plates were coated with Sm-RNP 
(Immunovision) or nucleosomes (USB Corporation, Cleveland, 
hio USA), respectively. 
 Rheumatoid factor: ELISA plates were coated with 10 μg/ml 
rabbit IgG (Jackson Immunoresearch, West Grove, Pennsylvania, 
USA) overnight at 4°C. Serum samples were diluted 1:100; 
C57BL/6 10-week mouse serum was used as negative control. 
 Figure 1  IRAK-M suppresses TLR7 and TLR9 signalling and lymphoproliferation in B6 lpr  mice. (A) Spleen monocytes were prepared from wild-
type mice (black bars) or Irak-m-defi cient mice (white bars) and stimulated with 1 µg/ml of lipopolysaccharide (LPS), imiquimod (Imi), CpG-DNA 
(CpG) or Y12-snRNP immune complexes as described in the Methods section. Supernatants were harvested after 24 h of stimulation and tumour 
necrosis factor α (TNFα) and interleukin (IL)-6 release were determined by ELISA. For immune complex stimulation, interferon α (IFNα) mRNA 
expression was determined by RT-PCR. Data represent mean±SEM from three independent experiments; *p<0.05 vs wild-type. (B) At 6 months of 
age, Irak-m-defi cient B6  lpr  mice showed splenomegaly (vertical arrows) and hyperplasia of cervical lymph nodes (horizontal arrows) compared with 
age-matched B6  lpr  control mice. Quantitative data on the right show weight of mesenterial lymph nodes and spleens. Data represent mean±SEM 
from at least 12 mice in each group; *p<0.05. (C) Immunofl uorescence staining of spleen sections from 6-month-old B6  lpr/Irak-m-/-  and B6 lpr  wild-type 
mice. Representative images are shown at an original magnifi cation of ×100. Lack of IRAK-M is associated with an expansion of CD3+ T cells (red) 
and CD11c+ dendritic cells (green) but not of CD19+ B cells (blue). Quantitative data based on immunofl uorescence staining on the right represent 
mean±SEM from at least 12 mice in each group; *p<0.05. 
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HRP-conjugated anti-mouse IgG was used as a secondary 
antibody. 
 Real-time quantitative (TaqMan) RT-PCR 
 Real-time (RT)-PCR was performed on mRNA from cells purifi ed 
from spleen by two-step magnetic cell sorting (Miltenyi Biotec) 
as previously described. 17 The SYBR Green Dye detection sys-
tem was used for quantitative RT-PCR on Light Cycler 480 
(Roche, Mannheim, Germany). Gene-specifi c primers (300 nM; 
Metabion, Martinsried, Germany) were used (see table 2 in 
online supplement). Controls consisting of ddH 2 O were nega-
tive for target and housekeeper genes. 
 Statistical analysis 
 One-way ANOVA followed by a post hoc Bonferroni test was 
used for multiple comparisons using GraphPad Prism Version 
4.03. Single groups were compared by the unpaired two-tailed 
Student t test. Data were expressed as mean±SEM. Survival 
curves were compared by Kaplan–Meier analysis using log-
rank two-tailed testing. Statistical signifi cance was assumed at 
p<0.05. 
 RESULTS 
 IRAK-M suppresses TLR7 and TLR9 signalling 
 IRAK-M is known to suppress TLR4 signalling at the kinase 
level, 21 which is shared by other TLRs. 32 We therefore hypoth-
esised that IRAK-M would also suppress TLR7 and TLR9 sig-
nalling. Spleen monocytes were prepared from wild-type and 
 Irak-m -defi cient mice and stimulated with the TLR4 agonist 
LPS, the TLR7 agonist imiquimod and the TLR9 agonist CpG-
DNA, or with immune complexes (Y12snRNP). All three TLR 
agonists induced the production of TNFα, IL-6 and expression 
of interferon α (IFNα) within 24 h in wild-type splenocytes, but 
 Irak-m -defi cient cells produced much more of these cytokines 
( fi gure 1A ). Thus, IRAK-M suppresses TLR7 and TLR9 signalling 
in addition to TLR4 signalling. 
 IRAK-M is induced in spleens and suppresses 
lymphoproliferation in B6  lpr  mice. 
 We fi rst carefully evaluated  Irak-m -defi cient B6 mice for signs 
of spontaneous autoimmunity but found no difference in 
lupus autoantibodies, serum cytokines and spleen immune 
cell numbers or state of activation from wild-type B6 mice up 
to 12 months of age (see table 1 in online supplement). Next 
we generated  Irak-m -defi cient B6  lpr  mice. The phenotype of 
homozygous B6  lpr  mice is introduced only by a single lupus 
susceptibility gene ( lpr ) which impairs Fas-induced apoptosis 
of autoreactive B and T cells. 8 Because B6  lpr  mice produce anti-
nuclear autoantibodies and minor immune complex glomerulo-
nephritis only late in life, litters of B6  lpr/Irak-m-/-  mice could be 
bred along Mendelian ratios from B6  lpr/Irak-m+/-  mice and revealed 
no weight gain differences compared with B6 mice (data not 
shown). For SLE phenotype analysis we fi rst evaluated IRAK-M 
mRNA expression in spleens of B6  lpr  mice and found IRAK-M 
mRNA to be increasingly expressed over time (data not shown). 
Next we compared the size of spleens and lymph nodes in 
6-month-old B6  lpr  and B6  lpr/Irak-m-/-  mice. The spleens and lymph 
nodes were signifi cantly enlarged in B6  lpr/Irak-m-/-  mice compared 
with B6  lpr  mice ( fi gure 1B ). This was evident from spleen and 
bulk lymph node weights. Spleen histomorphology in 6-month-
old mice showed that B6  lpr/Irak-m-/-  mice had lymph follicle hyper-
plasia with an expansion of T cell and CD11c+ dendritic cell 
areas while CD19+ B cell areas were similar to those of B6  lpr  
mice, also evidenced by a quantitative assessment of stained 
spleen scans ( fi gure 1C ). Thus, lack of IRAK-M accelerates lym-
phoproliferation in mice when introduced in the context of a 
single additional lupus susceptibility gene ( lpr ). 
 IRAK-M suppresses the activation of dendritic cells in 
B6  lpr  mice 
 IRAK-M modulates pathogen recognition in monocyte/
macrophages, 21  23 so we hypothesised that IRAK-M may mod-
ulate the activation of dendritic cells in B6  lpr  mice, cells that 
handle lupus autoantigens and regulate the expansion of auto-
reactive lymphocytes in SLE. Flow cytometry was performed 
to quantify and characterise the activation state of CD11c+ 
cells without additional stimuli directly after the spleen har-
vest at 6 months of age. CD11c+ and CD8+CD11c+ but not 
CD4+CD11+ cells were signifi cantly more in total number 
as well as positive for the activation marker CD40 or MHCII 
in  Irak-m -defi cient B6  lpr  mice ( fi gure 2A ). This was associ-
ated with increased mRNA levels of IL-6 and IL-12 and with 
the IFNα-dependent genes Mx1, Ifi t1, TLR7 and TLR9 in the 
CD11b+ splenocyte population ( fi gure 2B ). By contrast, IfNβ 
mRNA was not detectable in  Irak-m -defi cient B6  lpr  mice (not 
shown). Plasma cell differentiation and survival factors Baff/
BlyS and Bcl2 33 were also induced in  Irak-m -defi cient CD11b+ 
splenocytes ( fi gure 2B ). Consistent with increased dendritic 
cell activation, B6  lpr/Irak-m-/-  mice had higher serum levels of 
IL-12 than B6  lpr  mice ( fi gure 2C ). Thus, in autoimmune B6  lpr  
mice, IRAK-M suppresses dendritic cell activation—that is, 
their production of proinfl ammatory cytokines and factors 
that promote the differentiation of B cells into plasma cells and 
plasma cell survival. 
 IRAK-M suppresses T cell expansion and stabilises 
the potential of regulatory T cells to suppress T cells 
in B6  lpr  mice 
 Given its impact on dendritic cell activation, lack of IRAK-M 
might affect T cell populations in B6  lpr  mice. Consistent with 
the expansion of spleen T cell areas ( fi gure 1B ), the numbers 
of CD4+ and CD8+ T cells, CD4/CD8 double negative ‘auto-
reactive’ T cells and CD4+/CD25+/Foxp3 ‘regulatory’ T cells 
were all increased in the spleens of  Irak-m -defi cient B6  lpr  mice 
and expressed higher levels of the activation marker CD69 
( fi gure 3A ). The latter was consistent with increased FoxP3 
mRNA expression in CD4/CD25+ T cells ( fi gure 3B ). IRAK-M 
defi ciency-associated expansion of CD4 T cells did not affect 
the Th1/Th2 balance as the mRNA expression of Th1 mark-
ers (T-bet/IFNγ) and Th2 markers (GATA3/IL-4) were consis-
tently induced in these cells in B6  lpr/Irak-m-/-  compared with B6  lpr  
mice ( fi gure 3B ). Th17 cells and IL-17 mRNA expression were 
undetectable in mice of both genotypes. How does the expan-
sion of Tregs affect T cell proliferation in  Irak-m -defi cient B6 lpr 
mice? To answer this question we performed a T cell suppres-
sion assay by co-culturing CD4+CD25+, CD4+CD25 neg and 
APC derived from spleens of either  lpr or  Irak-m -defi cient B6 lpr 
mice. In both strains the same proportion of CD4+CD25+ cells 
stained positive for FoxP3 (data not shown). Interestingly, how-
ever, a signifi cantly decreased level of Treg-induced suppression 
was observed in cells derived from  Irak-m- defi cient B6 lpr mice 
(data not shown). To determine whether the loss of suppression 
is due to non-functional Tregs in  Irak-m- defi cient B6 lpr mice, we 
co-cultured Tregs derived from this strain with wild-type APC. 
Strikingly,  Irak-m- defi cient Tregs showed clearly reduced sup-
pression even in co-culture with wild-type APC or vice versa, 
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indicating a contribution of IRAK-M from both cell types ( fi g-
ure 3C ), which suggests that Tregs are dysfunctional in  Irak-m -
defi cient B6  lpr  mice. Together, IRAK-M suppresses the expansion 
of all T cells including the CD4/CD8 double negative autoreac-
tive T cells and stabilises the potential of Tregs to suppress T cell 
proliferation in B6  lpr  mice. 
 IRAK-M suppresses the expansion of plasma cells and 
subsequent lupus autoantibody production in B6  lpr  mice 
 Flow cytometry did not reveal any difference in numbers of 
mature B cells, follicular B cells and marginal zone B cells in 
spleens ( fi gure 3D ), which was consistent with the compa-
rable size of CD19+ B cell areas in spleens of B6  lpr  and B6  lpr/
Irak-m-/-  mice ( fi gure 1B ). However,  Irak-m -defi cient CD19+ B 
cells expressed higher levels of Bcl6 and Blimp1 mRNA (data 
not shown), two dedicated plasma cell differentiation and sur-
vival factors. 33 These—as well as the increased levels of Baff/
BlyS and Bcl2 expressed by CD11b+ cells ( fi gure 2B )—were 
consistent with increased numbers of plasma cells in spleens of 
 Irak-m -defi cient B6 mice ( fi gure 3D ). To see whether enhanced 
activation of dendritic cells and the expansion of T cells and 
plasma cells affect IgG and lupus autoantibody production, 
we collected serum samples at monthly intervals from mice 
of both genotypes and determined antibody levels by ELISA. 
 Irak-m -defi cient B6  lpr  mice developed more hypergammaglob-
ulinaemia than B6  lpr  wild-type mice, which was not signifi cant 
 Figure 2  IRAK-M and dendritic cell activation in B6  lpr  mice. (A) Spleen CD11c+ and dendritic cell subsets were quantifi ed in B6  lpr/Irak-m-/–  and B6  lpr  
wild-type mice by fl ow cytometry using diverse expression markers as described in the Methods section. Data represent mean±SEM from 10 mice 
in each group; *p<0.05 ; **p<0.01 vs B6  lpr  mice. (B) RNA was isolated from spleen CD11b+ cells from B6  lpr/Irak-m-/–  and B6  lpr  wild-type mice for 
real-time PCR analysis. Data are expressed as means of the ratio of the specifi c mRNA versus that of 18S rRNA ± SEM; *p<0.01 vs B6  lpr  mice. 
(C) Serum samples from 6-month-old B6 lpr/Irak-m-/–  and B6  lpr  wild-type mice were analysed for IL-12p40 by ELISA. Data are mean±SEM from at least 
seven mice in each group; *p<0.05 vs B6  lpr  mice. 
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 Figure 3  IRAK-M and lymphocyte subsets in B6  lpr  mice. (A) Flow cytometry was used to determine the total number of distinct T cell subsets 
in spleens of 6-month-old B6 lpr/Irak-m-/–  and B6  lpr  wild-type mice. The histogram shows mean±SEM values of 8–14 mice in each group; *p<0.05, 
**p<0.01, ***p<0.001 vs B6  lpr  mice. Representative FACS acquisition for T cells is shown. (B) Cellular mRNA was prepared from CD4+CD25– 
and CD4+CD25+ spleen cell isolates from B6 lpr/Irak-m-/-  and B6  lpr  wild-type mice and analysed by real-time PCR. Data are expressed as means of 
the ratio of the specifi c mRNA versus that of 18S rRNA ± SEM; *p<0.05 vs B6lpr mice. (C) Splenocytes derived from B6  lpr/Irak-m-/-  and B6  lpr  mice 
were analysed for CD25 and FoxP3 expression by fl ow cytometry. CD4+CD25– T effector (Teff) cells, CD4+CD25+ T regulatory cells (Tregs) 
and antigen-presenting cells (APCs) were isolated from splenocytes of wild-type, B6  lpr  or B6  lpr/Irakm-/-  mice. 7.5 × 10 4 Teff cells were stimulated 
with anti-CD3 antibody and cultured alone or together with increasing numbers of Tregs (0.5, 1, 2 and 4 × 10 4 ) in the presence of 2 × 10 4 APCs. 
Proliferation of Teff cells was determined after 3 days by the incorporation of BrdU detected by fl ow cytometry. Diagrams show the mean fl uorescence 
intensity of BrdU gated on CD4+FoxP3– cells. Error bars indicate SEM of n=3; *p< 0.01 for lpr vs IRAK-M/lpr at 1, 2 and 4 × 10 4 Tregs. (D) B 
cell subsets were determined by fl ow cytometry in spleens of 6-month-old B6 lpr/Irak-m-/-  and B6 lpr  wild-type mice (B220+IgM+IgD+ mature B cells; 
B220+CD21 high ,CD23 low marginal zone B cells; B220+CD21 low CD23 high follicular B cells; κ light chain+ CD138+ plasma cells). The histogram shows 
mean±SEM values of 8–14 mice in each group; ***p<0.001 vs B6  lpr  mice. Representative FACS acquisition for plasma cells is shown. 
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before 6 months of age and mostly affected the IgG 2c and IgG 3 
isotypes (data not shown). At that time, lack of IRAK-M had 
also increased the serum dsDNA autoantibody levels from all 
IgG isotypes ( fi gure 4A ). The specifi city of dsDNA autoanti-
bodies was confi rmed by the  Critidiae luciliae assay. Diluted 
serum from B6  lpr/Irak-m-/-  mice showed a much more intense 
binding to the dsDNA of the fl agellate`s kinetoplast than 
serum of B6  lpr  mice. In addition, lack of IRAK-M was associ-
ated with increased production of anti-Sm IgG, anti-SnRNP 
IgG and anti-nucleosome IgG from 5 months of age compared 
with B6  lpr  mice ( fi gure 4B ). In contrast, rheumatoid factor 
levels were not affected by the  Irak-m genotype ( fi gure 4B ). 
Lack of IRAK-M obviously accelerated autoantibody produc-
tion of all isotypes, an effect that antedates the development 
of hypergammaglobulinaemia of only selected IgG isotypes 
by 1–2 months. Thus, IRAK-M preferentially suppresses the 
expansion of autoreactive plasma cells and the production 
of numerous autoantibodies against nuclear RNA and DNA 
autoantigens in B6  lpr  mice. 
 IRAK-M protects B6  lpr  mice from fatal autoimmune tissue injury 
 SLE may be associated with little or even fatal autoimmune tis-
sue injury, 34 but B6  lpr  mice do not develop major tissue lesions 
and only mild glomerulonephritis from 6 months of age. 8  Irak-
m- defi cient B6  lpr  mice had signifi cant peribronchial mononuclear 
cell infi ltrates and pneumonitis ( fi gure 5A ) and a semiquantitative 
lung injury score of 2.6±0.1 for B6  lpr/Irak-m-/-  mice compared with 
0.3±0.2 for B6  lpr  mice (p<0.0001). Furthermore,  Irak-m defi ciency 
was associated with diffuse mesangioproliferative glomerulo-
nephritis, as indicated by PAS-positive matrix expansion, glom-
erular hypercellularity and capillary obstruction ( fi gure 5B ). The 
composite activity score for lupus nephritis was 7.9±0.8 in B6  lpr/
Irak-m-/-  mice and 3.4±0.4 in B6  lpr  mice (p=0.003). The composite 
chronicity score was 1.4±0.2 in B6  lpr/Irak-m-/-  mice and 0.0±0 in B6  lpr  
 Figure 4  IRAK-M and serum IgG and DNA autoantibodies in B6  lpr  mice. B6  lpr/Irak-m-/-  (white) and B6  lpr  wild-type mice (black) were bled at monthly 
intervals to determine plasma levels of (A) IgG dsDNA autoantibodies and (B) various lupus autoantibodies by ELISA. The isotype analysis of the total 
IgG and anti-DNA IgG are from 6 months only. Data represent mean±SEM values from at least six mice at each time point and genotype; *p<0.05 vs 
B6  lpr  mice at the same time point. 
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mice (p=0.0001). In  Irak-m -defi cient B6  lpr  mice, increased glomer-
ular damage was associated with increased glomerular positivity 
for C3c (0.4±0.1 for B6  lpr  mice vs 1.2±0.1 for B6  lpr/Irak-m-/-  mice, 
p=0.0005). Does the genotype-dependent autoimmune tissue 
injury affect the mortality of B6  lpr  mice? In  Irak-m -defi cient B6  lpr  
mice, 50% had died at 34 weeks of age while none of the B6  lpr  
mice had died up to 52 weeks of age ( fi gure 5C ), suggesting that 
IRAK-M is a gene that protects B6lpr mice signifi cantly from SLE 
and from SLE-related mortality Together, IRAK-M protects B6  lpr  
mice from systemic autoimmunity and also from fatal autoim-
mune tissue injury, mainly by suppressing the activation of APC 
and the expansion of autoreactive lymphocytes. 
 IRAK-M suppresses autoimmunity by inhibiting TLR7 signalling 
in B6  lpr  mice 
 The immunostimulatory effects of endogenous nucleic acids are 
known to drive SLE via TLR7. 35  36 We therefore speculated that 
 Irak-m defi ciency aggravated murine lupus mainly by uncou-
pling TLR7 signalling. To test this concept we treated additional 
cohorts of B6  lpr  and B6  lpr/Irak-m-/-  mice with a TLR7 inhibitor. 28 
 29 All mice were treated for 10 weeks and killed at 6 months 
of age. TLR7 blockade abrogated the accelerated kidney and 
lung disease in  Irak-m- defi cient B6  lpr  mice to the phenotype level 
of B6  lpr  mice ( fi gure 6A , B ). Most strikingly, none of the  Irak-m-
 defi cient B6  lpr  mice treated with TLR7 antagonist died during 
 Figure 5  Lung injury, lupus nephritis and overall survival in B6  lpr  mice. (A) Lung and (B) renal sections were stained with periodic acid-Schiff (PAS). 
Images are representative of at least 12 mice in each group. (C) Survival was studied in independent cohorts of mice and is illustrated as a Kaplan–
Meier curve. Note that B6  lpr/Irak-m-/–  mice (continuous line) reach 50% survival at 8 months of age while all B6  lpr  wild-type mice (broken line) survived 
until 12 months of age. 
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 Figure 6  TLR7 antagonism in B6  lpr  and B6  lpr/Irak-m-/–  mice. (A) Kidney and (B) lung sections were stained with periodic acid-Schiff (PAS). Images 
are representative of six B6  lpr/Irak-m-/-  mice in each group. The respective morphometric analyses for each organ from treated and untreated B6  lpr  
and B6  lpr/Irak-m-/–  mice are shown below. Kidney morphometry was separately scored for disease activity (white bars) and chronicity (black bars) as 
described in the Methods section. Data are mean±SEM values. (C) Flow cytometry was used to determine the total number of distinct T cell subsets 
in spleens of 6-month-old B6  lpr/Irak-m-/–  and B6  lpr  wild-type mice that had been treated with the TLR7 antagonist. The histogram shows mean±SEM 
values of 6–14 mice in each group; *p<0.05, **p<0.01 vs untreated Irak-m-defi cient B6  lpr  mice. B6  lpr/Irak-m-/–  were bled at month 6 to determine 
plasma levels of anti-snRNP and autoantibodies by ELISA (right histogram). Data represent mean±SEM values of 6–14 mice in each group; *p<0.05 
vs untreated Irak-m-defi cient B6  lpr  mice. 
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the study period; hence, TLR7 blockade prevented the prema-
ture lethality observed in  Irak-m- defi cient B6  lpr  mice. In contrast, 
TLR7 antagonism had only a minor and non-signifi cant effect on 
the mild SLE phenotype of B6  lpr  mice ( fi gure 6 ). TLR7 blockade 
completely reversed the expansion of spleen T cells including 
the CD4/CD8-negative ‘autoreactive’ T cells ( fi gure 6C ). TLR7 
blockade also reversed the increased levels of RNA (but not 
DNA) autoantibodies in  Irak-m- defi cient B6  lpr  mice ( fi gure 6C , 
 d ata not shown). We therefore conclude that  Irak- m defi ciency 
accelerates SLE in B6  lpr  mice by fostering TLR7 signalling. 
 DISCUSSION 
 TLR7 signalling contributes to autoimmunity 6  35 and IRAK-M 
suppresses TLR signalling, 21 so we hypothesised that IRAK-M 
might suppress autoimmunity. Our data support the latter by 
two lines of evidence. First,  Irak-m defi ciency aggravates the 
autoimmune phenotype and mortality of B6  lpr  mice. Second, 
TLR7 blockade almost entirely abrogates the aggravated auto-
immune phenotype of  Irak-m- defi cient B6  lpr  mice. 
 We selected B6  lpr  mice as an appropriate latent autoimmunity 
model because female B6  lpr  mice develop some lupus autoanti-
bodies but no major autoimmune tissue injuries. 8 The selection 
of  lpr mice on the C57BL/6 genetic background also allowed 
us to intercross them with  Irak-m -defi cient B6 mice to obtain 
and expand B6  lpr/Irak-m-/-  mice. Introducing  Irak-m defi ciency into 
B6  lpr  mice introduced premature mortality in these mice by dra-
matically accelerating their autoimmune phenotype in terms of 
autoantibody production and autoimmune tissue injury, both of 
which were earlier in onset and more severe at a given time 
point. As  Irak-m defi ciency alone did not cause autoimmunity 
in B6 mice, IRAK-M instead acts as a modifi er or enhancer gene 
together with the lpr mutation. Obviously the  Fas defi ciency 
provided by the  lpr mutation is suffi cient for loss of tolerance (ie, 
autoimmunity), but overt autoimmune disease requires at least 
another single genetic abnormality such as dysfunctional  Irak-m 
in B6  lpr  mice. These data are in line with studies that introduced 
 Tlr9 or  Sigirr defi ciency into B6  lpr  mice. 16  17 It is noteworthy that 
 Tlr9 or  Sigirr defi ciency both accelerate autoimmunity in lupus 
mice by enhancing TLR7 signalling in APC. 17  36  37 For SIGIRR, 
these fi ndings were also validated in pristane-induced lupus of 
B6 mice. 38 TLR7 signalling was recently found to contribute 
signifi cantly to lupus-like autoimmunity because ribonucleopro-
teins such as U1snRNP act as endogenous TLR7 agonists and 
activate dendritic cells and B cells such as viral RNA. 39 – 41 As 
such, TLR7 signalling induces type I interferons and interferon-
stimulated genes and enhances autoantigen presentation which 
fosters autoantigen-directed T and B cell responses (ie, autoim-
munity). 6  42 Our comparative phenotype analysis of B6  lpr  and 
B6  lpr/Irak-m-/-  mice showed that all of these aforementioned com-
ponents were also associated with the B6  lpr/Irak-m-/-  genotype. 
Because TLR7 antagonism almost entirely prevented the aggra-
vated autoimmune phenotype of B6  lpr/Irak-m-/-  mice, we conclude 
that  Irak-m defi ciency accelerates autoimmunity by uncoupling 
TLR7 signalling. Only the increased DNA autoantibody produc-
tion was TLR7-independent and should relate to enhanced TLR9 
signalling. 16 While the specifi city of the TLR7 antagonist used in 
this study is under debate, 43 its lack of modulating DNA autoan-
tibodies adds to the evidence for its specifi city by in vitro test-
ing. 28 IRAK-M has been shown to suppress TLR4 signalling by 
preventing the dissociation of IRAK1 and IRAK4 from the TLR/
MyD88 signalling complex as an essential element of the TLR 
downstream signalling cascade towards the activation of MAP 
kinases and NF-κB. 21 TLR7 (and TLR9) use the identical MyD88-
dependent signalling pathway, 32 which is consistent with our 
fi nding that  Irak-m -defi cient spleen monocytes display increased 
TNFα or IL-6 production on stimulation with TLR4, TLR7 or 
TLR9 agonists or other studies that observed increased TLR2 
and TLR7 signalling on  Irak-m silencing in RAM macrophages. 44 
A suppressive role of IRAK-M on autoimmune tissue injury is 
also anticipated by a recent study that found IRAK-M induction 
to be associated with repeated TLR7 agonist exposure which 
ultimately suppressed experimental allergic encephalomyelitis 
in mice. 45 
 In summary, lack of IRAK-M accelerates autoimmunity and 
autoimmune tissue injury of B6  lpr  mice by enhancing TLR7-
dependent pathomechanisms. Suppression of autoimmunity is 
a previously unknown function of IRAK-M. We identifi ed loss 
of function mutations in the IRAK-M gene that are previously 
unknown genetic risk factors for SLE and potentially also for 
other systemic autoimmune diseases. 
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